patent/TR-200102121-T2

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TR-200102121-T2

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b172e4dc6f8b115773eb99a04e8260f6
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
filingDate	2000-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02ca83d15bb5c60f4f97ea31b2081f60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_535f5ebccd55ef0fc95a6ec557fb92a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d88412338ddca1142937de38ef6a285 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b13c80bad3a7f34237ca83d10d4ae80
publicationDate	2002-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	TR-200102121-T2
titleOfInvention	The use of imidazo [1,5-a] pyrido [3,2-e] pyrazinones as preparations
abstract	The invention relates to the use of imidazo [1,5-a] pyrido [3,2-e] pyrazinones of the formula-1 for the treatment of erectile dysfunction (impotence) as inhibitors of phosphodiesterase 5. [1,5-a] pyrido [3,2-e] relates to the use of pyrazinones as a inhibitor of phosphodiesterase 3 for the treatment of heart disease, lung hypertension, and vascular diseases associated with hyposerpation.
priorityDate	1999-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID72758 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526450 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421355313 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411298829 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66876768 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1051

Total number of triples: 35.